Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Merit Financial Group LLC

Merit Financial Group LLC trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 68.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,145 shares of the medical equipment provider’s stock after selling 2,498 shares during the quarter. Merit Financial Group LLC’s holdings in Intuitive Surgical were worth $386,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. NBT Bank N A NY acquired a new stake in Intuitive Surgical during the 3rd quarter worth about $410,000. Advisor Partners II LLC raised its holdings in Intuitive Surgical by 2.3% during the 3rd quarter. Advisor Partners II LLC now owns 14,496 shares of the medical equipment provider’s stock worth $4,237,000 after buying an additional 332 shares during the period. Clear Harbor Asset Management LLC raised its holdings in Intuitive Surgical by 6.7% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 4,162 shares of the medical equipment provider’s stock worth $1,217,000 after buying an additional 262 shares during the period. TD Asset Management Inc raised its holdings in Intuitive Surgical by 7.1% during the 3rd quarter. TD Asset Management Inc now owns 1,020,452 shares of the medical equipment provider’s stock worth $298,268,000 after buying an additional 67,560 shares during the period. Finally, Klingenstein Fields & Co. LP raised its holdings in Intuitive Surgical by 1.0% during the 3rd quarter. Klingenstein Fields & Co. LP now owns 94,551 shares of the medical equipment provider’s stock worth $27,636,000 after buying an additional 928 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the transaction, the vice president now directly owns 26,877 shares in the company, valued at $10,349,795.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, EVP Myriam Curet sold 481 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $386.09, for a total transaction of $185,709.29. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at $115,054.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Marshall Mohr sold 108,790 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The disclosure for this sale can be found here. Insiders sold 147,927 shares of company stock worth $57,064,459 over the last three months. 0.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Mizuho upped their target price on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Jefferies Financial Group upped their target price on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Robert W. Baird dropped their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. Stifel Nicolaus upped their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, Raymond James upped their target price on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $388.65 on Wednesday. The stock has a market cap of $137.86 billion, a P/E ratio of 70.15, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The stock has a fifty day moving average price of $385.34 and a 200 day moving average price of $351.97.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the business earned $1.00 earnings per share. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.